New prostate cancer trial aims to cut fatigue and tailor therapy

NCT ID NCT06274047

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 31 times

Summary

This study tests a personalized approach to treating prostate cancer in men who still have detectable PSA after prostate removal surgery. Participants receive radiation therapy plus the drug apalutamide, with the goal of reducing fatigue and other side effects compared to standard care. The trial enrolls 120 men and is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

    Contact

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66103, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.